128 related articles for article (PubMed ID: 11099465)
1. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression.
Elkin M; Miao HQ; Nagler A; Aingorn E; Reich R; Hemo I; Dou HL; Pines M; Vlodavsky I
FASEB J; 2000 Dec; 14(15):2477-85. PubMed ID: 11099465
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
[TBL] [Abstract][Full Text] [Related]
3. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition.
Taras D; Blanc JF; Rullier A; Dugot-Senant N; Laurendeau I; Bièche I; Pines M; Rosenbaum J
Neoplasia; 2006 Apr; 8(4):312-8. PubMed ID: 16756723
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of prostate cancer xenografts by halofuginone.
Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
[TBL] [Abstract][Full Text] [Related]
6. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
Nagler A; Ohana M; Shibolet O; Shapira MY; Alper R; Vlodavsky I; Pines M; Ilan Y
Eur J Cancer; 2004 Jun; 40(9):1397-403. PubMed ID: 15177499
[TBL] [Abstract][Full Text] [Related]
7. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.
Leiba M; Cahalon L; Shimoni A; Lider O; Zanin-Zhorov A; Hecht I; Sela U; Vlodavsky I; Nagler A
J Leukoc Biol; 2006 Aug; 80(2):399-406. PubMed ID: 16769768
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells.
Tsai MY; Yang RC; Wu HT; Pang JH; Huang ST
Cancer Lett; 2011 Nov; 310(2):198-206. PubMed ID: 21788102
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
12. The angiosuppressive effects of 20(R)- ginsenoside Rg3.
Yue PY; Wong DY; Wu PK; Leung PY; Mak NK; Yeung HW; Liu L; Cai Z; Jiang ZH; Fan TP; Wong RN
Biochem Pharmacol; 2006 Aug; 72(4):437-45. PubMed ID: 16793023
[TBL] [Abstract][Full Text] [Related]
13. Nafoxidine modulates the expression of matrix-metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in endothelial cells.
De Lorenzo MS; Alonso DF; Gomez DE
Anticancer Res; 2000; 20(1A):395-400. PubMed ID: 10769686
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro.
Montesano R; Kumar S; Orci L; Pepper MS
Lab Invest; 1996 Aug; 75(2):249-62. PubMed ID: 8765325
[TBL] [Abstract][Full Text] [Related]
15. Novel function of ascorbic acid as an angiostatic factor.
Ashino H; Shimamura M; Nakajima H; Dombou M; Kawanaka S; Oikawa T; Iwaguchi T; Kawashima S
Angiogenesis; 2003; 6(4):259-69. PubMed ID: 15166494
[TBL] [Abstract][Full Text] [Related]
16. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
[TBL] [Abstract][Full Text] [Related]
17. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic function of tocotrienol.
Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor.
Morais C; Gobe G; Johnson DW; Healy H
Angiogenesis; 2009; 12(4):365-79. PubMed ID: 19882112
[TBL] [Abstract][Full Text] [Related]
20. Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo.
Kunimasa K; Ikekita M; Sato M; Ohta T; Yamori Y; Ikeda M; Kuranuki S; Oikawa T
Cancer Sci; 2010 Nov; 101(11):2462-9. PubMed ID: 20670297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
